Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07523555) titled 'Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies' on April 5.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Beijing Biotech
Condition:
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm
BPDCN
Relapsed/Refractory T-cell Acute Lymphoblastic Leu...